Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, it's ticking back up pretty fast. Up over 40% from just days ago and recovering much quicker than usual.... CNBX is movin' on up in a serious way and will see some valleys as people jump off as their comfort level is breached.
This is not a $ 1, $ 2, $ 10 stock. It is a $ 100 stock that is putting everything in place to be a major player if not the major player.
This is not BS. I got in at .03. I have studied it for going on 3 years. I see it beating GWPH and the others for multiple reasons.
Hi Pstats,
When you say huge spike, are you saying VDRM PPS is heading up or that shorts are going to spike and take it down?
Are you seeing enough data in the legal docs that you feel a paid membership is worth it for this stock alone?
Thank You, Jim
Hi Drigue,
What do you mean by "10q just hor"?
I of course understand the 10q part, but wasn't sure if hor was a typo or acronym.
Thank You, Jim
Hi StockWhale, I am not seeing news for today. What news are you referring to? Thank You, Jim
RE: "Plus we had news today too".
Well that deescalated quickly!! I have whiplash!!
FANTASTIC!!! I so needed a mega green day!!
Saw this in our local paper and went on the AP to find numerous outlets that carried it (posted links below).
Looks like "the government" is moving in the right direction away from traditional cancer treatments.
Let's hope that movement is a good sign for CNBX to be player, considering the great results it has been seeing.
"WASHINGTON
The government has recently approved the first cancer therapy that's based on a tumor's genetics instead of the body part the cancer struck first.
Now thousands of patients whose cancer is growing worse despite standard treatment can try this new therapy — as long as genetic testing of the tumor shows they're a candidate.
One oncologist says "it's like having a lottery ticket."
Read more here:
http://www.thestate.com/news/article159904064.html
http://www.miamiherald.com/news/article159904064.html
http://abcnews.go.com/Health/wireStory/tumor-gene-testing-urged-drug-targets-cancer-48475746
Is there any way to post what they have in the PDF?
Thank You, Jim
Same is done with most controlled medications, like phenobarbital.
The low dosage allows flexibility, so physicians can prescribe from a low dosage on up (10mg a day, 40mg a day, etc). To offset affects, the patient can take 4 in the morning, 4 at night, and get their full dose in a day without taking 1 big pill.
If a physician wants specific treatment, they can send a biopsy of the patient's cancer to CNBX and they will provide a personalized treatment regimen for the patient. The personalized approach has had 100% success across all cancers tested across two tests cycles over the past year and can be viewed at clinicaltrials.gov
The 100% is not my statement, that is available in various trial records and PR's.
Indeed, any company can do everything right on the R&D side and still fail due to bad management, but as for CNBX proving it can kill every cancer it has been tested on being a broad statement, that is a paraphrase of their recent PR's and results available at clinicaltrials.gov.
All of the reports have came back complete successes. Not all companies have that track record, which narrows the statement a bit in CNBX's favor.
CNBX studies has killed cancer without killing healthy cells in every cancer they have tested it on. The only company I know of that can claim that. GWPH has been over $ 100 for some time. If CNBX can do 1/2 to 2/3 of that, what a rise, and what a product for the world!!!
Funny you would mention that exact number, that is where I got in!
100,000 @ .018
100,000 @ .020
87,000 @ .040 when it looked like it was really going to run in the short term.
I wish I had stayed away from MCOA.... put $ 7,500 in it and dumped it at a $ 4,500 loss rather than ride it down. Should have considered the difference between medical and recreational, stayed away and put the $$$ into VDRM.
VDRM as noted, CNBX (various buys between .03 and .15), OWCP (1.60) are my holdings now.... and now we wait.
GLTA!!!!! Jim
It is low due to the time of the year. Heading into Fall and heading into Spring are when these stocks do well (remember that this stock went to $ 3 in September and surged again to over $ 7 at the end of February).
This stock has just recently pulled out of the red for the first time due to major investors and is now doing its work with more money on hand than ever. Doesn't change the cycle, but it does mean that the company will remain in the business of bringing in biopsies and prescribing the right cannabis levels to cure specific cancers in specific patients.
With Cannabics, you are at the beginning of a new industry. Chemotherapy and Radiation companies will fight tooth and nail, but Cannabics has proven that its methods kill cancer without killing healthy cells around the cancer, so it is just a matter of time before Cannabics and Israel take over cancer treatment for the world.
I guess a counter argument to your wife would be she can leave you now when Cannabics is down due to the cycle and costs to ramp up such an endeavor, but she will have to agree in the divorce not to return for higher alimony or child support when Cannabics sits at a price of $ 50 or more per share, which is about 1/2 of GWPH's value, and GWPH will not have the long term sales growth of Cannabics. If it was my wife, that is exactly how I would present it. If you leave when it is low, sign that you are not coming back when it swings the other way.
I have been studying CNBX since late 2014 and been an investor since July 2015 after completing my due diligence. This is the number one medical marijuana stock there is. Others may rise and fall faster, but CNBX is actually doing research that you can track at clinicaltrials.gov that show that people are doing great with this product and when this takes off, $ 50 to $ 100 a share is completely within reason.
Good luck to you, and if you are still holding CNBX shares, good luck to your wife finding anyone with a better portfolio than this will turn out to be by this time next year.
Jim
The full list of 11 Defendants. Dr. Otiko is not the only one fighting the good fight.
Defendant
Garret R. Adams
Defendant
Biogenx, Inc.
Defendant
R. Chris Cattone
Represented By
Tamara M. Leetham
Austin Legal Group, Apc
contact info
Thomas K. Wilka
Hagen, Wilka And Archer, P.C.
contact info
Sara E. Schroeder
Hagen, Wilka And Archer, P.C.
contact info
Defendant
Greentree Financial Group, Inc.
Represented By
Tamara M. Leetham
Austin Legal Group, Apc
contact info
Thomas K. Wilka
Hagen, Wilka And Archer, P.C.
contact info
Sara E. Schroeder
Hagen, Wilka And Archer, P.C.
contact info
Defendant
Howard Phillips, LLC
Represented By
Paul W. Tschetter
Boyce Law Firm, LLP
contact info
Defendant
Neurogenx Nerve Center
Defendant
Christopher Ayo Otiko
Represented By
Tamara M. Leetham
Austin Legal Group, Apc
contact info
Thomas K. Wilka
Hagen, Wilka And Archer, P.C.
contact info
Sara E. Schroeder
Hagen, Wilka And Archer, P.C.
contact info
Defendant
D. Howard Phillips
Represented By
Paul W. Tschetter
Boyce Law Firm, LLP
contact info
Defendant
Phillips Company
Represented By
Paul W. Tschetter
Boyce Law Firm, LLP
contact info
Defendant
ViaDerma, LLC
Represented By
Tamara M. Leetham
Austin Legal Group, Apc
contact info
Thomas K. Wilka
Hagen, Wilka And Archer, P.C.
contact info
Sara E. Schroeder
Hagen, Wilka And Archer, P.C.
contact info
Plaintiff
Steven J. Keough
522 N. Main Ave Apt 202
Sioux Falls, SD 57104
Sounds promising. Thanks for the info!
Here is the link at drugs.com:
https://www.drugs.com/otc/676986/viabecline.html
Thank you chico2663 and yes, $ 3 would be fantastic!!
Thanks again and go VDRM!!!!
I saw that by a little after 9:30am we had already broke 1 million trades. Fantastic!!
I know most are hoping for .50, but I have been locked in to selling off at $ 2 for awhile and may raise that. Bought my first 100,000 shares at .018 and have continued to add since. Will be interesting.
Thanks for the birthday wishes!!! Jim
Is the price dropping because of the 1 million shares at $ 1 and the dilution?
Everything is going great for this company: Investors pulling them out of the red, reports coming back 100% successful, a partnership with Israel's Ministry of Health (the only country authorized for global exporting), real time reports available on Clinicals.gov, what else does this company have to have going for it for the slide to stop?
If it is the 1 million shares at $ 1, then hopefully they exercise their option at another million shares at $ 2 soon and raise the price with their purchase!
So successful that they keep dropping in value doesn't sound like a common sense statement. Please enlighten me!!
Thank you, Jim
As I logged in to Etrade to confirm that VDRM has an Ask at .03, I said to myself: "Give me some good news. It's my birthday". It was at that moment I realized.... I sound like Gordon Gecko.
Here's to VDRM taking off and making our day even brighter!!!
Yes. Bought in from .018 up to .030 and I am in it till it hits at least .50. Planning for more like $ 2. So yep, locked and loaded.
Alan Brochstein wrote the BS article "Cannabics Pharmaceuticals Triggers Regulatory Scrutiny After Parabolic Spike" that caused CNBX to fall from $ 7+.
When I contacted the OTC board about his claims of "scrutiny" and provided them his article, they replied with the following denouncement that there had been no "scrutiny" of CNBX and stated that they believed Brochstein's article was a statement from CNBX, which it obviously was not.
Here is their reply regarding his article and their views of Brochstein speaking with any knowledge. Keep in mind the article title above regarding "Regulatory Scrutiny":
"Thank you for your email. Please note that OTC Markets has never announced a review of any nature regarding the company; and for further clarification, OTC Markets Group is not a regulatory agency. The links you included reference the company’s press release disseminated on February 23, 2017.
Please let us know if you have any additional questions.
Sincerely,
Gareth Colglazier
OTC Markets Group
100 M Street SE, Suite 220 / Washington, DC 20003
Office: (212) 896-4458
Email: gareth@otcmarkets.com"
So Brochstein claimed "regulatory scrutiny" of CNBX where there was none, and when I included his article in my email to OTC, (full article linked below), they thought it was from CNBX. Anyone that read the article would know CNBX did not put this out.
In short, Brochstein has already proven in the last 90 days to be a person that likes to claim knowledge he does not have, claim "regulatory scrutiny" where there has been none, and when his articles are provided to the OTC Board, they denounce him as probably a nut working to stir up CNBX or MM news and nothing more.
He has cost us enough. Do not give someone that OTC has gone on record as not having the knowledge he claims to have any more credence than he has already falsely given himself.
Jim
https://www.newcannabisventures.com/cannabics-pharmaceuticals-triggers-regulatory-scrutiny-after-parabolic-spike/
That's what I thought, but the article kind of made it seem that only the PE product was awaiting FDA approval.
Thank you for confirming AV2277. Jim
Is Viabecline already FDA approved and only waiting for approval on the Premature Ejaculation treatment?
"In addition to that, initial production for Viabecline, our topical antibiotic ointment is on track, and we have started a new independent study in Texas to prove Viabecline's efficacy in treating diabetic foot wounds. Our product for treating Premature Ejaculation is in its final stage of review for registration with the FDA," said Dr. Otiko. "The Company plans to continue to expand its Intellectual Property (IP) Portfolio in 2017."
Bid is .0172 Ask is .028 Biggest disparity I have seen in awhile!
Bid (Size) Ask (Size)
0.0172(10000) 0.028(194000)
Can someone please advise the press release writer to stop writing "recently released today" every time they do a PR for VDRM.
Whether describing the company or vehemently arguing the lawsuit, the use of such wording makes the PR seem poorly done.
Thanks, Jim
Today's Volume: 1,283,380. Average Volume (10 Days): 423,023.
To all of our new friends; "Welcome to the party pal". :)
500,000 share ASK at .018!!!! YES!!!
Does the lawsuit forbid going to market with the product while the case is pending?
I know that will not necessarily be spelled out in the case filing, but I am asking any legal experts if in their opinion a product can or / does not typically go to market with such a case pending.
Thank you for your time. Jim
Thank you for sharing your opinions on the stock. I know none of us have a crystal ball, but as odd as it may sound, I feel that reading the boards and opinions like yours gives a vibe of what is going on in investor's minds.
From those that do nothing but yell "rah rah, all hail CNBX", to those that say the company is being de-listed, if you read enough posts and can start to see patterns in the white noise, it is like reading the tea leaves of the investment community that takes the time to post here.
Thank you for your time!! Jim
Hi Wallywest. So, do you foresee there being another "spike of madness" that takes us back up around $ 3 or so or do you feel we are settling into our new reality and $ 1 to sub-dollar is where we will stay?
I got in between .03 and .15 and trying to decide whether to hold and see if we get another spike or sell off rather than riding it clear back down to sub-dollar.
I bought in because I believed in the company, which at that time was marketing the only long release MMJ pill. Now that we are marketing biopsies and other services that may take longer to see profit, I question whether to hold em or to fold em so to speak.
Thank you for your time and DD. Jim
Does anybody have any news regarding this nose dive and anything that is possibly going to save it?
Have been in it 2 years but kinda hate to ride it all the way back down.
Thanks, Jim
Thanks Midnightmatt, good to see you! BTW, OTCM got back with me and denied that they publicly released that they were "scrutinizing" or "reviewing" CNBX's sudden price surge back in February and that they would not release something like that.
While they acknowledged that it is a common practice to do such a review, they claim they had nothing to do with it getting out and that they have not found anything unscrupulous about CNBX's sudden rise in price.
While I was able to link numerous articles from before CNBX's reply, OTCM said the only article they were involved with was CNBX's reply after the news had broke. ?????
It would seem the good news regarding the trials you linked has not had the impact we would hope.
As people say: CNBX is the same company they were from before February 22nd and have even released more good news since. Let's hope CNBX can start trading back at the higher numbers again based on there not being an issue with their sudden rise in price.
Take care, Jim
Is there any good news anticipated to stop this slide?
PR in February stated "NEW Topical Antibiotic Ointment" when it stated: Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes Science and Technology.
That would lead one to believe this is a NEW ointment.
Before we continue adding additional products and end up with an exciting press release about "Viaderma Chip Dip & Salsa", I'd love for him to finish the ointment article and do a corresponding press release regarding the NEW ointment so that we can get some confirmation, from him, regarding the initial product we invested in.
And no, I am not asking for a new PR everyday. Just not a bs PR every week that avoids the topic we are all invested in.
I Requested Results of OTCM's Scrutiny of CNBX:
CNBX's credibility was severely damaged by an announcement made by OTC Markets February 21st, 2017 regarding the fact they were going to "scrutinize" CNBX for their recent stock price surge.
Now that CNBX has dropped five dollars in value, nothing has been reported by OTCM regarding their findings.
If you are going to announce scrutiny before announcing findings, you should have to also share the findings of the scrutiny, whether positive or negative.
Use the following email link if you would also like to ask OTCM to share their findings: http://www.otcmarkets.com/contactUs
Below is what I submitted to OTCM 4-9-17:
As noted in numerous articles below, on February 21st, 2017, OTC Markets announced that they were looking into Cannabics Pharmaceuticals (CNBX) due to their recent stock price surge.
The announcement of OTCM's "scrutiny" had an immediate cooling effect on the stock and it has not recovered since.
While it could possibly be said that the statement did not cause the stock price to drop, it has been almost 60 days since the announcement was made.
Can you please advise the current findings of the heightened scrutiny that OTCM announced?
If you are going to make announcements regarding such heightened scrutiny, proof of said scrutiny and the results of it should also be announced.
Those of us who had years worth of CNBX investments cut would like to know what the heightened scrutiny has found so as to act accordingly. (There would be no reason to announce the scrutiny ahead of findings if the positive or negative findings were not going to be shared publicly).
Thank you for your time and concern. James Patton
Following are just a few of the links to said announcement appearing in the press:
https://www.newcannabisventures.com/cannabics-pharmaceuticals-triggers-regulatory-scrutiny-after-parabolic-spike/
http://finance.yahoo.com/news/cannabics-pharmaceuticals-inc-provides-shareholders-140000767.html?soc_src=social-sh&soc_trk=tw
https://www.newcannabisventures.com/cannabics-pharmaceuticals-triggers-regulatory-scrutiny-after-parabolic-spike/
https://seekingalpha.com/instablog/6880-alan-brochstein-cfa/4963347-capitalize-cannabis-report-02-25-17
RE: Article Dr. Otiko was invited to write -
I sent an email to the Journal of Diabetes Science and Technology asking when Dr. Otiko's article will run in the JDST and received the reply pasted below.
So while it has not run yet, this confirms that Dr. Otiko WAS INVITED to write an article (which means he must be somebody that is on their radar to garner an invite to write) and also that there is some press on the way other than the PRNewsline and MarketWire online sites when they run his article.
Below is the correspondence:
Medina, Tiffany
9:52 AM (3 hours ago)
to me
Hi James,
As an update, this is an invited article that is going to be included in an upcoming special section of JDST. We’re working on getting a better idea of the timing of its release.
Thanks,
Tiffany
From: Medina, Tiffany
Sent: Tuesday, April 04, 2017 8:19 AM
To: 'James Patton'
Cc: Gamboa, Camille (camille.gamboa@sagepub.com)
Subject: RE: Automatic reply: Dr. Otiko Article
Surprised didn't pop more on the trials news.
From OTCMarkets.com, printout of Notification Of Late Filing:
They have till April 17th to get their yearly report in. Was held up due to awaiting info from a "3rd Party". Link is below:
http://www.otcmarkets.com/financialReportViewer?symbol=VDRM&id=168522
Stop Sign Defined: No Big Deal:
A Stop Sign Usually Means The Issuer is Simply Behind in its Quarterly and Annual Filings
When a Pink Sheet Issuer falls behind on the filing of its OTCMarkets financials and disclosures, it can be marked a stop sign (Pink No Information) on OTCMarkets.com. This also happens when a former OTCQB, or bulletin board Issuer ceases to fulfill its SEC reporting obligations. The bottom line here is that a Stop Sign is not in itself a “bad sign.”
Securities Attorneys Can Help Bring OTCMarkets Filings Current
If the only reason for the Stop Sign is that the Issuer is behind in its filing, and if those filings can be made current, then this presents an opportunity for new management. A securities attorney can call the helpful staff at OTCMarkets.com to review the history of the Issuer and find out if there is another other substantive issue that caused the Stop Sign. If not, then the matter is simple enough: the Issuer needs to subscribe to OTCMarkets’ Disclosure and News Service, and bring its filings current. The costs involved are easily quantifiable by securities lawyers like Matheau J. W. Stout, and it always makes sense to find out, even if an Issuer is not ready today to begin posting past due filings.
Issuers Marked Caveat Emptor Are Not Always Guilty of Wrongdoing
In contrast, Caveat Emptor (Skull and Crossbones) stocks are believed to have some negative element in their past history, which is significant enough for OTCMarkets.com to warn all prospective investors: Buyer Beware. In some cases, past management or promoters associated with the Issuer have become entangled in SEC problems unrelated to the Company, or are the subject of state inquiries. Sometimes there were actual violations of securities law that are connected to the Issuer itself, and sometimes there is simply a misunderstanding that can be fixed by presenting evidence to the regulatory authorities involved.